共 16 条
[1]
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study[J] . Andre Goy,Rajni Sinha,Michael E. Williams,Sevgi Kalayoglu Besisik,Johannes Drach,Radhakrishnan Ramchandren,Lei Zhang,Sherri Cicero,Tommy Fu,Thomas E. Witzig.Journal of Clinical Oncology . 2013 (29)
[2]
Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi[J] . Umberto Vitolo,Marco Ladetto,Carola Boccomini,Luca Baldini,Federico De Angelis,Alessandra Tucci,Barbara Botto,Annalisa Chiappella,Annalisa Chiarenza,Antonello Pinto,Amalia De Renzo,Francesco Zaja,Claudia Castellino,Alessia Bari,Isabel
[3]
Tandem Autologous–Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity[J] . Sandra Cohen,Thomas Kiss,Silvy Lachance,Denis Claude Roy,Guy Sauvageau,Lambert Busque,Imran Ahmad,Jean Roy.Biology of Blood and Marrow Transplantation . 2012 (6)
[5]
High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry[J] . Nicolas Mounier,Carmen Canals,Christian Gisselbrecht,Jan Cornelissen,Roberto Foa,Eulogio Conde,John Maertens,Michel Attal,Alessandro Rambaldi,Charles Crawley,Jian-Jian Luan,Mats Brune,Sebastian Wittnebel,Gordon Cook,G.W. van Imhoff,Michael Pfreundschuh,Anna Sureda.Biology of B
[6]
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial[J] . Gilles Salles,John Francis Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Réda Bouabdallah,John Vincent Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppa,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin I
[8]
Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas[J] . Erica D. Warlick,Marcie Tomblyn,Qing Cao,Todd DeFor,Bruce R. Blazar,Margaret MacMillan,Michael Verneris,John Wagner,Kathryn Dusenbery,Mukta Aurora,Veronika Bachanova,Claudio Brunstein,Linda Burns,Sarah Cooley,Dan Kaufman,Navneet S. Majhail,Brian McClune,Philip McGlave,Jeffrey Miller,Betul Oran,Arne Slungaard,Gregory Ve